MedPath

A phase IV, open-label, randomized, multicenter trial assessing a reyataz-based substitution approach in the management of lipodystrophy syndrome.

Conditions
HIV
MedDRA version: 6.1Level: PTClassification code 10049287
Registration Number
EUCTR2004-002740-10-IT
Lead Sponsor
BRISTOL-M.SQUIBB
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
300
Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary end point(s): ;Main Objective: ;Secondary Objective:
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath